Hypotensive and lipid regulatory actions of 4-hydroxyderricin, a chalcone from Angelica keiskei, in stroke-prone spontaneously hypertensive rats.
1. Previously, we found that Angelica keiskei extract (ethyl acetate extract from the yellow liquid of stems) elevated serum high-density lipoprotein (HDL) levels and reduced liver triglyceride content in stroke-prone spontaneously hypertensive rats (SHRSP). To identify the active substance in A. keiskei extract, we examined the effect of 4-hydroxyderricin, a characteristic chalcone isolated from the yellow liquid of stems, on blood pressure and lipid metabolism in SHRSP. 2. Six-week-old male SHRSP were fed diets containing 0.07% 4-hydroxyderricin for 7 weeks with free access to the diet and water. Elevation of systolic blood pressure was significantly suppressed after 7 weeks treatment. Serum very low-density lipoprotein (VLDL) levels were significantly reduced, without any effect on HDL levels, and were associated with a significant decrease in the serum concentration of free fatty acids. 3. In the liver, significant decreases in relative liver weight and triglyceride content were found after treatment with 4-hydroxyderricin for 7 weeks. 4. An investigation of hepatic mRNA expression of proteins involved in lipid metabolism indicated that a significant decrease in microsomal triglyceride transferprotein may be responsible for the decrease in serum VLDL levels and that significant decreases in adipocyte determination and differentiation factor 1 and fatty acid synthase may be responsible for the decrease in hepatic triglyceride content. 5. In conclusion, dietary 4-hydroxyderricin produces suppression of the elevation of systolic blood pressure, reduction of serum VLDL levels and a decrease in hepatic triglyceride content in SHRSP.
Ogawa
Hiroshi
H
Department of Hygiene, Kinki University School of Medicine, Ohno-Higashi, Osaka-Sayama City, Osaka, Japan. ogawa-h@med.kindai.ac.jp
Ohno
Mami
M
Baba
Kimiye
K
D029969:Angelica / Q000737:chemistry*; D000818:Animals; D000959:Antihypertensive Agents; D001053:Apolipoproteins / Q000097:blood / Q000737:chemistry; D001794:Blood Pressure / Q000187:drug effects; D002599:Chalcone / Q000031:analogs & derivatives* / Q000494:pharmacology*; D002790:Cholesterol 7-alpha-Hydroxylase / Q000037:antagonists & inhibitors / Q000378:metabolism; D004032:Diet; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D000960:Hypolipidemic Agents; D050356:Lipid Metabolism; D008074:Lipoproteins / Q000097:blood / Q000737:chemistry; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D010936:Plant Extracts / Q000627:therapeutic use; D018547:Plant Stems / Q000737:chemistry; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D011918:Rats, Inbred SHR; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000959:Antihypertensive Agents; D001053:Apolipoproteins; D004791:Enzyme Inhibitors; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D010936:Plant Extracts; D012333:RNA, Messenger; C068243:4-hydroxyderricin; D002599:Chalcone; D002790:Cholesterol 7-alpha-Hydroxylase